Table 2.
Results of generalized EUD-based TCP for protocol 1 of clinical trial of recurrent H&N cancer.
| Patient no. | DBNCT,min
(Gy-w) |
gEUD (Gy) |
TCP (%) |
Response* |
|---|---|---|---|---|
| 1 | 6.0 (GTV1) 15.3 (GTV2) |
21.5 (GTV1) 47.2 (GTV2) |
0.2 (GTV1) 51.6 (GTV2) |
PD |
| 2 | 6.5 | 21.1 | 0.2 | SD |
| 3 | 10.0 | 42.3 | 30.8 | PR |
| 4 | 12.3 | 41.0 | 25.9 | PR |
| 5 | 9.2 | 31.9 | 4.4 | SD |
| 6 | 19.5 | 68.6 | 95.5 | CR |
| 7 | 7.0 (GTV1) 22.3 (GTV2) |
22.4 (GTV1) 63.6 (GTV2) |
0.3 (GTV1) 92.0 (GTV2) |
PD |
| 8 | 25.3 (GTV1) 19.0 (GTV2) |
80.7 (GTV1) 56.5 (GTV2) |
98.7 (GTV1) 81.8 (GTV2) |
CR |
| 9 | 18.5 | 49.8 | 62.3 | CR |
| 10 | 9.4 | 44.7 | 40.9 | PR |
| 11 | 7.9 | 35.7 | 10.3 | PD |
*Accessed using Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).